#postinjection

[jlburnsjr]

I never inject without it @alastinskincare Read what Senior Beauty Editor, @diannamazzone from @allure had to say about her experience receiving cosmetic filler and using our very own INhance Post-Injection Serum®️! #alastinskincare #alastin #postinjection #filler #cosmeticprocedure #cosmeticprocedures #lips #lipfiller (at Dr. John Burns - Dallas Plastic Surgery Institute) https://www.instagram.com/p/CNWecWLH8q1/?igshid=24yxbcnt4941

[faithnself]

#coloring #stressrelief #coloringbynumber #takingiteasy #postinjection #lovethewaythisonepops https://www.instagram.com/p/CEb8QIiJjqG/?igshid=6r7ugcm8335n

[delicatemagazinedreamer]

Viscosupplementation: Intralesional Treatment, Aspiration and Injection of Joints and Periarticular Tissue

The use of intraarticular hyaluronates for the treatment of pain in osteoarthritic joints is known as Viscosupplementation. There are two types of agents in use. Hylan G-F 20, a high-molecular-weight preparation, is one of them (molecular weight of 6,000,000). The other kind contains hyaluronan preparations with molecular weights ranging from 800,000 to 2,000,000. In patients with osteoarthritis, viscosupplementation is frequently useful in reducing pain (OA). 15,16 When compared to intraarticular corticosteroids, viscosupplementation offers the advantage of a delayed onset of action that lasts longer.

Viscosupplementation carries a number of dangers. In the authors' experience, postinjection pain is prevalent, however it is not always linked with a substantial effusion. A pseudo–septic effusion coupled with pyrexia is another consequence. 20 Until the results of the culture, these reactions necessitate hospitalisation and intravenous antibiotics. The relative benefits of hylan G-F 20 and lower-molecular-weight compounds are still a point of contention. 18,19 Although these agents were developed for the knee, they have proven to be effective in treating other joints such as the trapeziometacarpal joint, the shoulder, the hip, and the ankle.

Read more @ https://digitalgrowinfo.blogspot.com/2022/02/what-is-viscosupplementation-and-how.html

[sharistonecom]

Lip Augmentation in Your 20s – Is it a Good Idea?

Cosmetic lip augmentation consists of the enlargement and reshaping of otherwise normal lips to improve their dimensional relation with the patient’s nose, teeth, and surrounding facial structures. The appearance of the lips is determined by the spatial relation of the lip structures with the teeth in a 3-dimensional space and by their function during animation and speech.

Lip enhancement is a well-known plastic surgery operation for men and women in their 20s. That’s largely because there are so many ways to plump up your lips, ranging from surgical to non-surgical options. Lip filler, for example, is a sought-after injectable because it’s simple, fast, and risk-free. Nevertheless, there are other methods that can enhance your pout and give you lavish lips. The question is, should you do this? It’s up to you to decide.

Your decision to ‘plump’ or not is a spin-off from the Instagram generation. where large, super-kissable lips are part of the insta wallpaper.  If you can get a few more likes or followers to your latest selfie then a hour at the cosmetic surgeon is a small price to pay.

DIFFERENT KINDS OF LIP AUGMENTATION Let’s start with a discussion of the various methods available to give your lips some juicy, kissable appeal. By far, injectable techniques are the most popular. They are likely to cost a bit less than surgical options and you can usually have the treatment done swiftly. Visit the office, have the treatment, and then go on about your day.

On planet-celebrity,  you have different options as well, although the technique used is mostly the same. Your plastic surgeon or aesthetician will inject a filler after examining your lips, their shape and current fullness, and the planes and proportion of your face. A qualified, skilled doctor will ensure that the fillers will add to your appearance and work with your facial form.

As for the filler used, that will hinge on the surgeon. Fillers such as Juvederm, Perlane, Restylane, and Voluma are the most typical options. You can discuss the pros and cons of each with your plastic surgeon.

You can opt for surgical lip augmentation, as well. Lip implants offer a more permanent solution than lip fillers, which need to be repeated every six to eight months. Implants also allow you to choose more volume and fullness. Your lips are first sterilised, then anesthetized. This is usually a procedure that occurs in the office, so it’s fairly fast, too. Recuperation time shouldn’t last long at all.

Fat grafting is yet another alternative. As the name suggests, the process entails taking fat tissue from a different spot on your body and infusing it into your lips. The cosmetic surgeon will harvest fat from around your belly button, purify it, and then inject it to your lips. This procedure is good for five years or more and doesn’t tend to take longer than half an hour.

ADVANTAGES OF PLUMPING YOUR POUT IN YOUR 20’S.

Once you know your options, we should discuss why you might want to look into lip augmentation in your 20s. Lips are big right now. Look at all the cosmetic lip kits available. They’re fantastic, but you may get tired of over-drawing your lip liner to make your lips look fuller. Lush lips are gorgeous, but filling them in with makeup takes a lot of time, and not everyone has that skill. Lip fillers and other types of augmentation can save time and even money, at least in the long run.

When performed by a reputable surgeon, lip augmentation also looks natural. That can’t always be said for over-lined lips. You must consult with your doctor beforehand, though. He or she will help you decide on the most flattering size and shape.

The main reason to consider plumping your pout in your 20s is that it can stave off the signs of ageing. As you age, your body simply produces less collagen. That not only causes fine lines and wrinkles to embed themselves more deeply in your skin, but it can also cause your lips to thin out and droop.

Before the Operation.

Refraini from aspirin, Motrin, Aleve, fish oil, multivitamins, and vitamin E for about a week before your appointment, as each can act as a blood-thinner and contribute to postinjection bruising.

After the Operation

After-care is minimal.

Postinjection, your life can resume—despite some fear-mongering articles you might find online. According to Green, the only thing you should stay away from is aspirin. You can even toast your new look with a glass or two of wine. “Some people say you shouldn’t drink alcohol before filler because you can bruise, but I haven’t seen a huge difference after,” she said. As for ice, the doctor will put a cold pack on your lips after your filler’s been applied and will encourage you to use more if you’re feeling sore, but there’s no need sit with it for hours on end. The real swelling goes down in a day or two.

Doctors are unanimous that it makes sense: not to drinkfrom a straw right after your injections, and not sipping hot liquids— you’ll still be numb and might burn yourself. Ouch.

The post Lip Augmentation in Your 20s – Is it a Good Idea? appeared first on Best Cosmetic Surgeons.

source https://bestcosmeticsurgeons.com/lip-augmentation-in-your-20s-is-it-a-good-idea/ source https://bestcosmeticsurgeons.tumblr.com/post/620917975712677888

[jlburnsjr]

View this post on Instagram

A post shared by John Burns, MD, FACS (@drjohnburns)

I won’t inject without it. @alastinskincare Cosmetic injectables are some of the most popular non-surgical cosmetic procedures out there. So why not make them even better with INhance Post-Injection Serum? It helps to: 💉 Helps to accelerate recovery from post-injection bruising & swelling. 💉 Works with the skin to clear out damaged elastin and collagen. 💉 Supports the production of new, healthy elastin and collagen. 💉 Improves skin hydration and plumpness. 💉 The cooling applicator tip provides a soothing effect during treatment application. #alastin #alastinskincare #postinjection #cosmeticfillers #lipfiller #medspa #medicalgradeskincare (at Dr. John Burns - Dallas Plastic Surgery Institute) https://www.instagram.com/p/CG1RhkeHZX2/?igshid=g9ihfqee0hb9

[tptcca]

Novel app may help anticipate opioid overdose

A recently developed app identified changes in breathing patterns that preceded likely opioid overdoses, as well as during an actual overdose, according to a report recently published in Science Translational Medicine.

“Existing, human-based approaches to diagnose overdose rely on medical-grade equipment or trained recognition of diagnostic signs of opioid toxicity system. … Validating the efficacy of any opioid toxicity system requires access to patients and data while high-risk opioid use occurs, which is difficult because this can represent a medically life-threatening situation, Rajalakshmi Nandakumar, a PhD candidate at the Paul G. Allen School of Computer Science and Engineering, University of Washington, and colleagues wrote.

Researchers created an algorithm that used sonar to monitor patients’ breathing rate and identify when an opioid overdose has occurred. The app accurately identified respiratory depression, apnea and gross motor movements tied to acute opioid toxicity.

The app, named Second Chance, was then tested in 209 patients that used the legally-sanctioned supervised injection facility in Vancouver, British Columbia.

“We asked participants to prepare their drugs like they normally would, but then we monitored them for a minute pre-injection so the algorithm could get a baseline value for their breathing rate,” Nandakumar said in a press release. “After we got a baseline, we continued monitoring during the injection and then for 5 minutes afterward, because that’s the window when overdose symptoms occur.”

Researchers found that Second Chance identified postinjection, opioid-induced central apnea with 96% sensitivity and 98% specificity. The app also identified respiratory depression with 87% sensitivity and 89% specificity.

Nandakumar and colleagues also tested Second Chance in 20 simulated overdose events in the operating room during routine induction of general anesthe

  The post Novel app may help anticipate opioid overdose appeared first on Turning Point Treatment Center, Inc..

from https://www.turningpointtreatmentcenter.com/novel-app-may-help-anticipate-opioid-overdose/

[cancersfakianakis1]

Impact of external cooling with icepacks on 68 Ga-PSMA uptake in salivary glands

Abstract

Background

External cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included. Twenty-four patients were scanned with unilateral (solely left-sided) icepacks; 20 with bilateral icepacks; 45 without icepacks. Icepacks were applied approximately 30 minutes prior to tracer injection. PET/CT acquisition started 1 hour postinjection. Radiotracer uptake was measured in the parotid- and submandibular glands.

Results

When comparing the intervention group with the control group, uptake in the left parotid gland significantly differed: SUVmax: 11.07 ± 3.53 versus 12.95 ± 4.16; p = 0.02. SUVpeak: 9.91 ± 3.14 versus 11.45 ± 3.61; p = 0.04. SUVmax and SUVpeak were reduced with 14.52% and 13.45%. All other SUV values did not significantly differ. Patients with bilateral icepacks showed no significant differences in PSMA uptake compared to the control group (all: p > 0.05). Intra-patient analysis revealed some significant differences in SUVmax and SUVpeak between the cooled and non-cooled parotid gland (SUVmax: 11.12 ± 3.71 versus 12.69 ± 3.75; p = 0.00. SUVpeak: 9.93 ± 3.32 versus 11.25 ± 3.25; p = 0.00).

Conclusions

Impact of icepacks on PSMA uptake seems to be limited to the parotid glands. As clinical relevance of these findings is debatable, structural application of icepacks in the setting of lutetium-177 PSMA therapy needs careful consideration.

https://ift.tt/2Ktex7A

[itsmedicinesfakianakis]

Point-of-Care Ultrasonography Findings and Care Use Among Patients Undergoing Ultrasound-Guided Shoulder Injections.

Objective: The aims of the study were to assess the overall reduction of pain in patients undergoing ultrasound-guided shoulder injections and to characterize the preinjection point-of-care ultrasound findings and use of clinical services postinjection including the use of magnetic resonance imaging and surgeries. Design: Data of 172 patients who underwent ultrasound-guided subacromial subdeltoid injection or glenohumeral joint injection were reviewed for preinjection point-of-care ultrasound findings, change in pain intensity at 2 mos from baseline, and use of care at 6 mos’ postinjection. Pain intensity was measured by the numeric rating scale and a dichotomous report of global impression of significant improvement in pain. Responders were defined as those with 50% or more reduction in numeric rating scale or those with global impression of 50% or more improvement. Results: There were 141 responders among the 172 patients analyzed. Full-thickness rotator cuff tears were higher in the ultrasound-guided subacromial subdeltoid injection group when compared with the glenohumeral joint injection group (P = 0.038) and abnormal bicipital tendon findings higher in the glenohumeral joint injection group (P = 0.016). There were no significant differences in specific abnormal U findings between responders versus nonresponders. Twelve patients had a shoulder magnetic resonance imaging and four patients underwent operative interventions after the injection. Conclusions: Overall pain reduction after ultrasound-guided shoulder injections was favorable in the short term. There was no specific preinjection point-of-care ultrasound findings associated with clinical pain reduction after injection. Additional imaging and operative intervention after ultrasound-guided shoulder injections seemed to be relatively low. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2uiO5Az

from OtoRhinoLaryngology - Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vmP4E3

[hcsmca]

Relative effectiveness of additive pain interventions during vaccination in infants [Research]

BACKGROUND:

Vaccine injections can cause acute pain and distress in infants, which can contribute to dissatisfaction with the vaccination experience and vaccine hesitancy. We sought to compare the effectiveness of additive pain interventions administered consistently during vaccine injections in the first year of life.

METHODS:

We conducted a multicentre, longitudinal, double-blind, add-on, randomized controlled trial. Healthy infants were randomly assigned to 1 of 4 levels of pain management for all vaccine injections at 2, 4, 6 and 12 months: (i) placebo control; (ii) parent-directed video education about infant soothing; (iii) the video plus sucrose administered orally or (iv) the video plus sucrose plus liposomal lidocaine applied topically. All infants benefit from injection techniques that minimize pain. We used a double-dummy design; hence all parents watched a video (active psychological intervention or placebo) and all infants received oral solution (sucrose or placebo) and topical cream (lidocaine or placebo). We assessed infant distress during 3 phases — preinjection (baseline), vaccine injection (needle), and 1 minute postinjection (recovery) — using the Modified Behavioural Pain Scale (range 0–10). We compared scores between groups and across infant ages using a mixed-model repeated-measures analysis.

RESULTS:

A total of 352 infants participated in the study, from Jan. 17, 2012, to Feb. 2, 2016. Demographics did not differ among intervention groups (p > 0.05). Baseline pain scores did not differ among intervention groups (p = 0.4), but did differ across ages (p < 0.001). Needle pain scores differed among groups (p = 0.003) and across ages (p < 0.001). The mean (± standard deviation) needle score was 6.3 (± 0.8) in the video–sucrose–lidocaine group compared with 6.7 (± 0.8) in each of the other groups. There were no other between-group differences. Recovery scores did not differ among groups (p = 0.98), but did differ across ages (p < 0.001).

INTERPRETATION:

Only liposomal lidocaine provided consistent analgesia within an additive pain intervention regimen during vaccinations in infants. Trial registration: ClinicalTrials.gov, no. NCT01503060

Read more from CMAJ

[cancersfakianakis1]

Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 and 64 Cu-ATSM, improves therapeutic efficacy in a small animal tumor model

Abstract

Background

The present study proposed a new concept for targeted radionuclide therapy (TRT) to improve the intratumoral distribution of radioactivity using two different radiopharmaceuticals. We examined the efficacy of a combination of a tetrameric cyclic Arg-Gly-Asp (cRGD) peptide-based radiopharmaceutical, 64Cu-cyclam-RAFT-c(-RGDfK-)4 (64Cu-RaftRGD, an αVβ3 integrin [αVβ3] tracer), and 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM, a supposed tracer for hypoxic metabolism) in a small animal tumor model.

Results

Mice with subcutaneous αVβ3-positive U87MG glioblastoma xenografts were used. The intratumoral distribution of a near-infrared dye, Cy5.5-labeled RAFT-c(-RGDfK-)4 (Cy5.5-RaftRGD), 64Cu-RaftRGD, and 64Cu-ATSM was visualized by fluorescence imaging and autoradiography of the co-injected Cy5.5-RaftRGD with 64Cu-RaftRGD or 64Cu-ATSM at 3 h postinjection. Mice were treated with a single intravenous dose of the vehicle solution (control), 18.5 or 37 MBq of 64Cu-RaftRGD or 64Cu-ATSM, or a combination (18.5 MBq of each agent). The tumor volume, tumor cell proliferation, body weight, survival, and tumor and organ uptake of radiopharmaceuticals were assessed. It was shown that Cy5.5-RaftRGD colocalized with 64Cu-RaftRGD and could be used as a surrogate for the radioactive agent. The intratumoral distribution of Cy5.5-RaftRGD and 64Cu-ATSM was discordant and nearly complementary, indicating a more uniform distribution of radioactivity achievable with the combined use of 64Cu-RaftRGD and 64Cu-ATSM. Neither 64Cu-RaftRGD nor 64Cu-ATSM showed significant effects on tumor growth at 18.5 MBq. The combination of both (18.5 MBq each) showed sustained inhibitory effects against tumor growth and tumor cell proliferation and prolonged the survival of the mice, compared to that by either single agent at 37 MBq. Interestingly, the uptake of the combination by the tumor was higher than that of 64Cu-RaftRGD alone, but lower than that of 64Cu-ATSM alone. The kidneys showed the highest uptake of 64Cu-RaftRGD, whereas the liver exhibited the highest uptake of 64Cu-ATSM. No obvious adverse effects were observed in all treated mice.

Conclusions

The combination of 64Cu-RaftRGD and 64Cu-ATSM achieved an improved antitumor effect owing to the more uniform intratumoral distribution of radioactivity. Thus, combining different radiopharmaceuticals to improve the intratumoral distribution would be a promising concept for more effective and safer TRT.

https://ift.tt/2M4KlMq

[cancersfakianakis1]

89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors

Purpose: We evaluated biodistribution and tumor targeting of 89Zr-lumretuzumab before and during treatment with lumretuzumab, a human epidermal growth factor receptor 3 (HER3)-targeting monoclonal antibody. <p>Experimental design: 20 patients with histologically confirmed HER3-expressing tumors received 89Zr-lumretuzumab and underwent Positron Emission Tomography (PET). In Part A, 89Zr-lumretuzumab was given with additional, escalating doses of unlabeled lumretuzumab and scans were performed 2, 4 and 7 days postinjection to determine optimal imaging conditions. In Part B, patients were scanned following tracer injection before (baseline) and after a pharmacodynamic (PD)-active lumretuzumab dose for saturation analysis. HER3 expression was determined immunohistochemically in skin biopsies. Tracer uptake was calculated as standardized uptake value (SUV).</p> <p>Results: Optimal PET conditions were found to be 4 and 7 days after administration of 89Zr-lumretuzumab with 100 mg unlabeled lumretuzumab. At baseline using 100 mg unlabeled lumretuzumab, the tumor SUVmax was 3.4 (±1.9) at 4 days postinjection. SUVmean for normal blood, liver, lung and brain tissues were 4.9, 6.4, 0.9 and 0.2, respectively. Saturation analysis (n=7) showed that 4 days after lumretuzumab administration, tumor uptake decreased by 11.9% (±8.2), 10.0% (±16.5) and 24.6% (±20.9) at PD-active doses of 400, 800 and 1600 mg, respectively, when compared to baseline. Membranous HER3 was completely downregulated in paired skin biopsies already at and above 400 mg lumretuzumab.</p> <p>Conclusions: PET imaging showed biodistribution and tumor specific 89Zr-lumretuzumab uptake. Although, PD-active lumretuzumab doses decreased 89Zr-lumretuzumab uptake, there was no clear evidence of tumor saturation by PET imaging as the tumor SUV did not plateau with increasing doses.

http://ift.tt/2eCYe92

[cancersfakianakis1]

Response of Selenium and Selenogenome in Immune Tissues to LPS-Induced Inflammatory Reactions in Pigs

Abstract

Circulating concentration of the essential trace element selenium (Se) was significantly lower in inflammatory disorders. Although Se plays physiological roles mainly through the function of 25 selenoproteins, the response of the selenogenome in immune tissues during inflammatory reactions remains unclear. The objective of this study was to determine the Se retention and selenogenome expression in immune tissues during the lipopolysaccharide (LPS)-induced inflammatory response in porcine. A total of 12 male pigs were randomly divided into two groups and injected with LPS or saline. After 4 h postinjection, blood samples were collected and pigs were euthanized. Pigs challenged with LPS had 36.8 and 16.6 % lower (P < 0.05) Se concentrations in the serum and spleen, respectively, than those injected with saline. Moreover, the activities of GPX decreased (P < 0.05) by 23.4, 26.6, and 30.4 % in the serum, thymus, and lymph node, respectively, in the pigs injected with LPS. Furthermore, the LPS challenge altered (P < 0.05) the mRNA expression of 14, 16, 10, and 6 selenoprotein genes in the liver, spleen, thymus, and lymph node, respectively. Along with 10 previously reported selenoprotein genes, the response of Txnrd2, Txnrd3, Sep15, Selh, Seli, Seln, Selo, Selt, Selx, and Sephs2 to inflammatory reaction in immune tissues were newly illustrated in this study. In conclusion, the LPS-induced inflammatory response impaired Se metabolism and was associated with dysregulation of the selenogenome expression in immune tissues.

http://ift.tt/2ob53lB

[cancersfakianakis1]

First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas

Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and external beam radiotherapy (EBRT) for preoperative treatment of adults with locally advanced soft tissue sarcoma (STS).

Experimental Design: Patients had a preoperative indication of EBRT for STS of the extremity or trunk. Baseline tumor volume (TV) was calculated by MRI. NBTXR3 was injected percutaneously into tumors at 53.3 g/L. Dose escalation was based on four levels equivalent to 2.5%, 5%, 10%, and 20% of baseline TV. NBTXR3 was visualized in the tumor 24 hours postinjection, and EBRT was initiated (50 Gy over 5 weeks). Surgery was performed 6 to 8 weeks after EBRT completion.

Results: Twenty-two patients completed NBTXR3 injection, EBRT, and surgery and were followed for a median 22 months (range, 6–40). At NBTXR3 20% of TV, two dose-limiting toxicities occurred: injection-site pain and postoperative scar necrosis. The RD was defined as 10%. No leakage of NBTXR3 into surrounding tissues occurred; intratumor NBTXR3 levels were maintained during radiotherapy. At the RD, median tumor shrinkage was 40% (range 71% shrinkage, 22% increase); median percentage of residual viable tumor cells was 26% (range, 10%–90%). Patients receiving 20% of TV demonstrated pathologic complete responses. Seven grade 3 adverse events occurred, which were reversible.

Conclusions: A single intratumoral injection of NBTXR3 at 10% of TV with preoperative EBRT was technically feasible with manageable toxicity; clinical activity was observed. Clin Cancer Res; 23(4); 908–17. ©2016 AACR.

http://ift.tt/2l6FOwx